Preparation method of oseltamivir-based toxic impurity B

Through a series of specific chemical reaction steps, the problem of missing preparation method of base poison impurity B during oseltamivir synthesis is solved, and the preparation of high-purity oseltamivir toxic impurity B is achieved, ensuring drug safety and toxicity Research needs.

CN118930455APending Publication Date: 2024-11-12CHONGQING YUYANG PHARMACEUTICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411146461.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

During the synthesis of oseltamivir, there is a lack of synthetic method reports on the base toxic impurity B, which makes it difficult to prepare the impurity for toxicological research and drug safety monitoring.

Method used

High-purity oseltamivir virginity is prepared by a series of specific chemical reaction steps, including BOC protection amino reaction, Michael addition reaction, substitution reaction, azide reaction and boc removal reaction, using specific solvents and reagents. Impurity B.

Benefits of technology

It provides a stable and easy-to-operate method to successfully prepare high-purity oseltamivirki toxic impurity B, meeting the needs of drug safety and toxicological research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
Patent Text Reader

Abstract

The invention discloses an efficient chemical synthesis method of an oseltamivir-based poison impurity B.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical synthesis, and in particular, relates to a method for preparing oseltamivir-based toxic impurity B. Background Art

[0002] The molecular formula of oseltamivir is C 16 H 28 N204, chemical name: (3R, 4R, 5S)-4-acetamide-5-amino-3-(pentane-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester, Oseltamivir is a specific inhibitor acting on neuraminidase, a potent and highly selective influenza virus NA inhibitor (NAIs), which inhibits the action of neuraminidase and can inhibit the mature influenza virus from escaping from the host cell, thereby inhibiting the spread of influenza virus in the human body to play a role in treating influenza. Oseltamivir is a successful case of rational drug design based on structure. In the research and development of this drug, computer-aided drug design methods were widely used. According to the three-dimensional structure of the target enzyme, a highly efficient, low-toxic and highly specific neuraminidase inhibitor was designed in a targeted manner.

[0003] Roche Pharmaceuticals Ltd. is the patent holder of oseltamivir, and the oseltamivir phosphate capsules they produce are the only oseltamivir preparation on the market.

[0004] Oseltamivir is a class of neuraminidase analogs. The earliest drug of this type is zanamivir developed by GlaxoSmithKline. Since the physical and chemical properties of zanamivir are not conducive to biological absorption, the drug has low bioavailability, a single route of administration, and poor patient compliance. Oseltamivir is obtained by rational drug design based on zanamivir, the molecular structure of the natural substrate of neuraminidase, and the spatial structure of the catalytic center of neuraminidase. It is another drug successfully obtained by rational drug design after HIV integrase inhibitors.

[0005] In the process of synthesizing oseltamivir, a process impurity (3S, 4R, 5S)-4-acetamido-5-amino-2-azido-3-(pentan-3-yloxy)cyclohexane-1-carboxylic acid ethyl ester is generated. This impurity is a base toxic impurity for synthesizing oseltamivir. In the process of drug development and production, it is necessary to prepare this base toxic impurity B for toxicological research. When synthesizing oseltamivir, it is necessary to track and monitor the base toxic impurity B of oseltamivir to ensure the safety and effectiveness of the drug. After searching, there is no report on the synthesis of this impurity. Therefore, the present invention provides a method for synthesizing this impurity, which has practical significance for preparing impurity standards. Summary of the invention

[0006] The purpose of the present invention is to provide a new method for preparing oseltamivir-based toxic impurity B. The specific reaction formula is as follows: .

[0007] Specifically, the technical solution of the present invention is a method for preparing oseltamivir-based toxic impurity B.

[0008] The following steps are involved: Step 1: Add a base and di-tert-butyl dicarbonate to pure oseltamivir in a dichloromethane solvent to carry out a BOC amino protection reaction to synthesize compound 1; Step 2: Compound 1 is added with a base and p-methylthiophenol in tetrahydrofuran solvent to carry out Michael addition reaction to synthesize compound 2; Step 3: Add a base and iodomethane to compound 2 in DMF solvent to carry out a substitution reaction to synthesize an intermediate compound 3; Step 4: Add water and sodium azide to the intermediate compound 3 in DMF solvent to carry out azidation reaction to synthesize compound 4; Step 5: Add trifluoroacetic acid to compound 4 in dichloromethane solvent to carry out BOC removal reaction to synthesize oseltamivir-based toxic impurity B.

[0009] The base described in the above step 1 is sodium hydroxide, and the optimal molar amount is 3 times that of oseltamivir; the ratio of dichloromethane to water in the above step 1 is 1:1; the optimal reaction temperature in the above step 1 is 25-35°C.

[0010] The base described in the above step 2 is triethylamine, and the optimal molar amount is 0.6 times that of compound 1.

[0011] The base described in the above step 3 is sodium hydride, and the optimal molar amount is 1.2 times that of compound 2; in the above step 3, the ratio of sodium hydride to methyl iodide is 1:1.

[0012] The amount of water in the above step 4 is optimally 5% of DMF.

[0013] In the above step 5, the ratio of dichloromethane to trifluoroacetic acid is 1:1.

[0014] The invention provides a novel method for preparing high-purity oseltamivir-based toxic impurity B. The method is stable and easy to operate. DETAILED DESCRIPTION

[0015] 1. Preparation of compound 1.

[0016] In a 1000ml three-necked flask, 36g (0.9mol) of sodium hydroxide, 89.6ml (0.39mol) of di-tert-butyl dicarbonate, 235ml of water and 470ml of dichloromethane were added. The temperature was controlled to 25-35°C and stirred, and 93.7g (0.3mol) of pure oseltamivir (content greater than 99%) was added in portions to react. The temperature was controlled to 25-35°C and stirred for 5 hours. After the reaction was completed, 235ml of water was added to the reaction solution and stirred to separate the layers. The reaction solution was dried over anhydrous sodium sulfate and filtered. The mother liquor was evaporated to dryness under reduced pressure and rotary distillation. 200ml of isopropanol was added and stirred for crystallization at room temperature for 1 hour. The filter cake was washed with 25ml of isopropanol. The solid was dried at 45-55°C at normal pressure for 8 hours to obtain 99.2g of compound 1 solid, with a yield of 80.2%.

[0017] 2. Preparation of compound 2.

[0018] In a 1000ml three-necked flask, add 82.5g (0.2mol) of compound 1, 16.7ml (0.12mol) of triethylamine, 27.3g (0.22mol) of p-methylthiophenol and 495ml of tetrahydrofuran, control the temperature to 15-25℃ and stir to react for 3 hours. After the reaction is completed, add acetic acid to the reaction solution to neutralize the excess alkali, adjust Ph to neutral, evaporate the solvent under reduced pressure, add 150ml of isopropyl ether, stir and crystallize at room temperature for 1 hour, filter, wash the filter cake with 25ml of isopropyl ether, and dry the obtained solid at 45-55℃ under normal pressure for 4 hours to obtain 87.9g of compound 2 solid, with a yield of 82%.

[0019] 3. Preparation of compound 3.

[0020] Add 80.4 g (0.15 mol) of compound 2 and 402 ml of DMF to a 1000 ml three-necked flask, control the temperature to 20-30°C, add 4.3 g (0.18 mol) of sodium hydrogen in portions while stirring, stir and react for 0.5 hours, cool the solution to 0°C, add 11.2 ml (0.18 mol) of iodomethane, stir and react at room temperature overnight. After the reaction is completed, pour the reaction mixture into water, extract with 250 ml of dichloromethane × 5 times, combine the organic layers, dry with anhydrous sodium sulfate, filter, and evaporate the mother liquor under reduced pressure to dryness to obtain compound 3 as an oil (about 152 g), which is directly used in the next step.

[0021] 4. Preparation of compound 4.

[0022] In a 1000ml three-necked flask, add 16.3g (0.25mol) of sodium azide, 304ml of DMF, and 10ml of water, stir and dissolve, wash the oily compound 3 obtained in the previous step (about 152g) into the dropping funnel with 304ml of DMF, control the temperature to 25-35℃ and drop it into the reaction solution (about 2.5h), and stir and react for 4 hours. After the reaction is completed, pour the reaction solution into 400ml of dichloromethane and 400ml of water, stir and pour it into a separating funnel to stand and separate, wash 5 times with 400ml of water, combine the dichloromethane layer, dry with anhydrous sodium sulfate, filter, and evaporate the mother liquor under reduced pressure and rotary evaporation, add 150ml of isopropanol and stir and crystallize at 0℃ for 1 hour, filter, wash the filter cake with 20ml of isopropanol, and dry the solid at 45-55℃ at normal pressure for 5 hours to obtain 45.8g of compound 4 solid, yield: 67%.

[0023] 5. Preparation of Oseltamivir-based toxic impurity B.

[0024] In a 500ml three-necked flask, add 45.5g (0.1mol) of compound 4, 182ml of dichloromethane, and 182ml of trifluoroacetic acid, stir to dissolve, and react at room temperature of 20-30℃ for 3.5 hours. After the reaction is completed, spin dry the solvent, add saturated sodium bicarbonate aqueous solution to adjust the pH to 8, stir and pour into a separatory funnel, add ethyl acetate to extract 300ml × 3 times, combine the ethyl acetate layers, wash once with 300ml of sodium chloride aqueous solution, dry with anhydrous sodium sulfate, filter, vacuum rotary evaporate the mother liquor, add 91ml of isopropanol and stir at 0℃ for 1.5 hours to crystallize, filter, wash the filter cake with 15ml of isopropanol, and dry the solid at 45-55℃ at normal pressure for 6 hours to obtain 32.3g of oseltamivir base poison impurity B solid, yield: 91%.

Claims

1. A method for preparing an oseltamivir-based toxic impurity B having a structural formula as shown below: , The synthetic route of this method is as follows: , (1) Adding a base and di-tert-butyl dicarbonate to pure oseltamivir in a dichloromethane solvent to carry out a BOC amino protection reaction to synthesize compound 1; (2) Compound 1 obtained in step 1 is subjected to Michael addition reaction by adding a base and p-methylthiophenol in tetrahydrofuran solvent to synthesize compound 2; (3) Compound 2 obtained in step 2 is subjected to substitution reaction by adding a base and iodomethane in a DMF solvent to synthesize an intermediate compound 3; (4) The intermediate compound 3 obtained in step 3 is subjected to an azidation reaction by adding water and sodium azide in a DMF solvent to synthesize compound 4; (5) Compound 4 obtained in step 4 is subjected to a boc removal reaction by adding trifluoroacetic acid in a dichloromethane solvent to synthesize oseltamivir-based toxic impurity B.

2. In the preparation method according to claim 1, the base described in the above step 1 is sodium hydroxide, and the optimal molar amount is 3 times that of oseltamivir.

3. In the preparation method according to claim 1, in the above step 1, the ratio of dichloromethane to water is 1:

1.

4. In the preparation method according to claim 1, the optimal reaction temperature in the above step 1 is 25-35°C.

5. In the preparation method according to claim 1, the base described in the above step 2 is triethylamine, and the optimal molar amount is 0.6 times that of compound 1.

6. In the preparation method according to claim 1, the base described in the above step 3 is sodium hydrogen, and the optimal molar amount is 1.2 times that of compound 2.

7. In the preparation method according to claim 1, in the above step 3, the ratio of sodium hydrogen sulfide to methyl iodide is 1:

1.

8. In the preparation method according to claim 1, the amount of water in the above step 4 is optimally 5% of DMF.

9. In the preparation method according to claim 1, in the above step 5, the ratio of dichloromethane to trifluoroacetic acid is 1:1.